Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

- Study Met Primary Endpoint of Reduction of Time to Recovery   - Additional Analyses Ongoing to Understand Other Clinical Outcome Data   - Lilly's Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib Continues INDIANAPOLIS , Sept.